PPT-Dual Maintenance ART with RTV-Boosted Darunavir + Lamivudine

DUALGESIDA Dual Maintenance ART with RTVBoosted Darunavir Lamivudine DUAL GESIDA Study Design Source Pulido F et al Clin Infect Dis   20176521128 DRV RTV 3TC. Caruana. Alexandru. . Niculescu-Mizil. Presented by . Varun. . Sudhakar. An Empirical Comparison of Supervised Learning Algorithms. Importance:. Empirical comparison of different learning algorithms provides answers to questions such as. GENERIC ARVs. Tim Horn. Treatment Action Group. tim.horn@treatmentactiongroup.org. Federal AIDS Policy Partnership Meeting. December 2014. Patents and Exclusivity 101 . Myriad Policies. Patents issued >1996 have term of 20 years. Learning Objectives. EARLY VS DEFERRED ART. The Case is Made. Should Early-Stage Asymptomatic HIV Patients Receive ART? . The INSIGHT START Study. The CD4 Cell Count As a Measure . of Immune Deficiency in HIV Patients. Program. Improving Health. . . Promoting Wellness. QUARTERLY . SUMMARY. 2nd Quarter. July-September 2017. 2017/2018 Ryan White Grant Year. COUNTY HEALTH DEPARTMENTS . BY PHARMACY CATEGORY. PUTNAM. MARION. PROTEA Trial. Darunavir/r . M. onotherapy. versus Triple Therapy . PROTEA. : Study Design. Source: . Antinori. A, et al. . J Int AIDS Soc. 2014;17:19525.. Darunavir 800 mg QD. + Ritonavir 100 mg . QD. SWORD-1 . and SWORD-. 2. Dolutegravir plus Rilpivirine as Maintenance Dual Therapy. SWORD-1 and SWORD-2: Design. Source: . Llibre. JM, et al. Lancet. 2018;39:839-49.. Background. : . Identical, randomized, multinational, open-label, industry-sponsored, parallel-group, . Dovato. ). Last Updated: November 28, 2022. Prepared by:. Brian R. Wood, MD. David H. Spach, MD. Dolutegravir-Lamivudine. Photograph courtesy of . ViiV. INSTI. NRTI. 50 mg. 300 mg. Dolutegravir-Lamivudine. Lopinavir. -RTV in Treatment Experienced. TITAN Trial. Darunavir/. r . versus Lopinavir/r in Treatment-Experienced . TITAN. : Study Design. Source: . Madruga. JV, et al. Lancet. 2007;370:49-58. . Darunavir. FLAMINGO. Dolutegravir + 2 NRTIs versus Darunavir + RTV + 2 NRTIs . FLAMINGO: Study Design. Source: . Clotet. B, et al. . Lancet. 2014;383:2222-31. . Dolutegravir + . TDF-FTC or ABC-3TC. (n = 242). Darunavir + Ritonavir + . POTENT Trial. Tipranavir. /. r . versus Darunavir. /r . in Treatment-Experienced . POTENT. : Study Design. Source: . Elgadi. MM, et al. . Drugs R D. . 2011;11:. 295-. 302.. Tipranavir. . + . R. itonavir BID . DRIVE FORWARD. Doravirine. + 2 NRTIs vs. Darunavir + Ritonavir + 2 NRTIs. DRIVE FORWARD: Design. Source: Molina J-M, et al. Lancet HIV. 2018;5:e211-20.. Doravirine. + 2 NRTIs. (n = 385). Darunavir + RTV + 2 NRTIs. POWER 1 and 2. Darunavir. /. r versus other PIs in Treatment-Experienced . POWER 1 and 2. : Study Design. Source: . Clotet. B, et al. . Lancet. . 2007;369:. 1169-78.. Darunavir BID + RTV BID + OBR . RADAR Trial. Raltegravir. + Darunavir/r versus TDF-FTC + Darunavir/r. RADAR: Study Design. Source: . Bedimo. RJ, et al. . PLoS. One. 2014;9:e106221.. Darunavir QD + Ritonavir QD + Raltegravir BID . NEAT001/ANRS 143 Trial. Darunavir/r + Raltegravir versus Darunavir/r + TDF-FTC. NEAT001/ANRS143: Study Design. Source: . Raffi. F, et al. Lancet. 2014;384:1942-51. .. Darunavir + Ritonavir QD. + Raltegravir BID .